Mird-237 [new] -
The discovery that miR-237 and its human homolog miR-125b sensitize cells to radiation opens up exciting avenues for the future of (treatments given in addition to primary therapies). 1. Overcoming Radioresistance
While the theoretical and experimental foundations are solid, transforming miRNA discoveries into standard clinical treatments takes time. Current oncological research is focused on . MIRD-237
The development of the MIRD-237 as a therapeutic agent was a result of extensive research and collaboration between nuclear medicine physicians, oncologists, and radiopharmaceutical manufacturers. The isotope was initially produced through the irradiation of Ytterbium-176 with neutrons in a nuclear reactor. However, this method had limitations, including low yields and high production costs. The discovery that miR-237 and its human homolog
MIRD-237 holds substantial promise for the treatment and diagnosis of certain cancers. Its potential clinical applications include: Current oncological research is focused on